Will a Three-Pronged Approach be the Better Approach?

A promising way to further improve outcomes in this disease appears to be the development of adjuvant therapeutic strategies. This trial will treat children with high-risk neuroblastoma by combining anti-GD2 with mIBG therapy and a new antibody (Nivolumab).

Project Title: A Phase 1 Study of 131-1 mIBG, Nivolumab and ch14.18/CHO in relapsed / refractory neuroblastoma.
Researcher:  Juliet Gray, MD
Institution: University Hospital Southampton, UK/University of Wisconsin, Madison, US/University Hospital Greifswald, Germany
Study Type: Phase I clinical trial
Status:  Open in the UK. Not yet open in the US and Germany.

Neuroblastoma, the most common extracranial solid tumor in children, remains one of the major challenges in pediatric oncology. A promising way to further improve outcomes in this disease appears to be the development of adjuvant therapeutic strategies. This trial will treat children with high-risk neuroblastoma by combining anti-GD2 with mIBG therapy and a new antibody (Nivolumab).

Immunotherapy with the anti-GD2 antibody has been shown to increase the number of children with neuroblastoma who stay in remission, and has become a standard component of treatment.  Nevertheless, a large number of children still relapse and ultimately die from their disease.

mIBG therapy uses the mIBG molecule to deliver radiotherapy directly to neuroblastoma cells, and is already widely used in children with relapsed or poorly responding tumors.

Nivolumab targets a molecule in the immune system, PD-1, boosting the patient’s own immunity to cancer, and has already shown considerable promise in adult cancers.

The three different types of therapy appear to work together to generate strong, protective immunity to neuroblastoma, achieving long-term tumor cure.  This collaborative project will be the first testing ever of this combination of therapies and will be conducted in four hospitals in the UK, US, and Germany.

To learn more about this trial, visit clinicaltrials.gov